-
M.
Guazzi,
M.
Vicenzi,
R.
Arena,
M.
Guazzi
(2009)
Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction: A Target of Phosphodiesterase-5 Inhibition in a 1-Year Study
Circulation, 124
-
E.
Kaluski,
I.
Kobrin,
R.
Zimlichman,,
A.
Marmor,
Oscar
Krakov,
O.
Milo,
A.
Frey,
S.
Kaplan,
R.
Krakover,
A.
Caspi,
Z.
Vered,
G.
Cotter
(2003)
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Journal of the American College of Cardiology, 41 2
-
M.
Humbert,
O.
Sitbon,
A.
Yaici,
D.
Montani,
D.
O’Callaghan,
X.
Jaïs,
F.
Parent,
L.
Savale,
D.
Natali,
S.
Günther,
A.
Chaouat,
F.
Chabot,
J.
Cordier,
G.
Habib,
V.
Gressin,
Z.
Jing,
R.
Souza,
G.
Simonneau
(2010)
Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
European Respiratory Journal, 36
-
R.
Badagliacca,
B.
Pezzuto,
R.
Poscia,
M.
Mancone,
S.
Papa,
S.
Marcon,
G.
Valli,
G.
Sardella,
F.
Ferrante,
C.
Iacoboni,
D.
Parola,
F.
Fedele,
C.
Vizza
(2012)
Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy: the impact of late referral.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 31 4
-
R.
Benza,
Dave
Miller,
M.
Gomberg-Maitland,
R.
Frantz,
A.
Foreman,
C.
Coffey,
A.
Frost,
R.
Barst,
D.
Badesch,
C.
Elliott,
T.
Liou,
M.
Mcgoon
(2010)
Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
Circulation, 122
-
L.
Spieker,
V.
Mitrović,
G.
Noll,
R.
Pacher,
M.
Schulze,
J.
Muntwyler,
C.
Schalcher,
W.
Kiowski,
T.
Lüscher
(2000)
Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure
Journal of the American College of Cardiology, 35
-
W.
Cornwell,
V.
McLaughlin,
Sangeetha
Krishnan,
M.
Rubenfire
(2011)
Does the outcome justify an oral-first treatment strategy for management of pulmonary arterial hypertension?
Chest, 140 3
-
J.
McMurray,
J.
Teerlink,
G.
Cotter,
R.
Bourge,
J.
Cleland,
G.
Jondeau,
H.
Krum,
M.
Metra,
C.
O'connor,
J.
Parker,
G.
Torre-Amione,
D.
Veldhuisen,
J.
Lewsey,
A.
Frey,
M.
Rainisio,
I.
Kobrin
(2007)
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
JAMA, 298 17
-
D.
Zisman,
M.
Schwarz,
K.
Anstrom,
H.
Collard,
K.
Flaherty,
G.
Hunninghake
(2010)
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.
The New England journal of medicine, 363 7
-
M.
Packer,
J.
McMurray,
B.
Massie,
A.
Caspi,
V.
Charlon,
A.
Cohen-Solal,
W.
Kiowski,
W.
Kostuk,
H.
Krum,
B.
Levine,
P.
Rizzon,
J.
Soler,
K.
Swedberg,
S.
Anderson,
D.
DeMets
(2005)
Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.
Journal of cardiac failure, 11 1
-
I.
Anand,
J.
McMurray,
J.
Cohn
(2004)
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelin-A Receptor Antagonist Trial in heart failure (EARTH): Randomised, double-blind, placebo-controlled trial
Acc Current Journal Review, 13
-
T.
Thenappan,
Sanjiv
Shah,
S.
Rich,
Lu
Tian,
S.
Archer,
M.
Gomberg-Maitland
(2009)
Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation
European Respiratory Journal, 35
-
R.
Agarwal,
M.
Gomberg-Maitland
(2011)
Current therapeutics and practical management strategies for pulmonary arterial hypertension.
American heart journal, 162 2
-
G.
Lewis,
R.
Shah,
K.
Shahzad,
J.
Camuso,
P.
Pappagianopoulos,
J.
Hung,
A.
Tawakol,
R.
Gerszten,
D.
Systrom,
K.
Bloch,
M.
Semigran
(2007)
Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension
Circulation, 116
-
R.
Benza,
Dave
Miller,
R.
Barst,
D.
Badesch,
A.
Frost,
M.
Mcgoon
(2012)
An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry.
Chest, 142 2
-
O.
Minai,
S.
Nathan,
N.
Hill,
D.
Badesch,
J.
Stoller
(2010)
Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns.
Respiratory medicine, 104 5
-
M.
Humbert,
O.
Sitbon,
A.
Chaouat,
M.
Bertocchi,
G.
Habib,
V.
Gressin,
A.
Yaïci,
E.
Weitzenblum,
J.
Cordier,
F.
Chabot,
C.
Dromer,
C.
Pison,
M.
Reynaud‐Gaubert,
A.
Haloun,
M.
Laurent,
E.
Hachulla,
V.
Cottin,
B.
Degano,
X.
Jaïs,
D.
Montani,
R.
Souza,
G.
Simonneau
(2010)
Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
Circulation, 122
-
T.
Thenappan,
C.
Glassner,
M.
Gomberg-Maitland
(2012)
Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension.
Chest, 141 3
-
P.
Kalra,
J.
Moon,
A.
Coats
(2002)
Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?
International journal of cardiology, 85 2-3
-
R.
Agarwal,
Sanjiv
Shah,
A.
Foreman,
C.
Glassner,
S.
Bartolome,
Z.
Safdar,
S.
Coslet,
A.
Anderson,
M.
Gomberg-Maitland
(2012)
Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 31 5
-
C.
O'connor,
W.
Gattis,
K.
Adams,
V.
Hasselblad,
B.
Chandler,
A.
Frey,
I.
Kobrin,
M.
Rainisio,
M.
Shah,
J.
Teerlink,
M.
Gheorghiade
(2003)
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
Journal of the American College of Cardiology, 41 9
